Kymera Therapeutics Inc (KYMR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2026 | 12-2025 | 09-2025 | 06-2025 | 03-2025 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 144,090 | 357,011 | 112,949 | 335,816 | 89,966 |
| Marketable Securities | 506,839 | 491,265 | 392,733 | 329,629 | 373,184 |
| Receivables | N/A | N/A | N/A | 40,000 | N/A |
| Other current assets | 0 | 0 | 0 | 0 | 20,000 |
| TOTAL | $677,432 | $871,214 | $528,298 | $728,327 | $500,951 |
| Non-Current Assets | |||||
| PPE Net | 41,617 | 43,175 | 45,128 | 48,572 | 49,172 |
| Investments And Advances | 894,724 | 771,158 | 473,055 | 297,629 | 312,335 |
| Other Non-Current Assets | 55,243 | 57,265 | 55,563 | 56,540 | 55,854 |
| TOTAL | $991,584 | $871,598 | $573,746 | $402,741 | $417,361 |
| Total Assets | $1,669,016 | $1,742,812 | $1,102,044 | $1,131,068 | $918,312 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 12,839 | 4,015 | 5,506 | 5,781 | 10,263 |
| Accrued Expenses | 35,095 | 42,274 | 28,639 | 27,976 | 23,117 |
| Other current liabilities | 976 | 242 | 408 | 117 | 893 |
| TOTAL | $62,643 | $83,212 | $71,575 | $87,540 | $58,989 |
| Non-Current Liabilities | |||||
| Deferred Revenues | N/A | 22,925 | 23,279 | 40,000 | 11,476 |
| Other Non-Current Liabilities | 65,585 | 67,034 | 68,450 | 69,835 | 71,182 |
| TOTAL | $66,736 | $79,936 | $84,211 | $72,048 | $73,090 |
| Total Liabilities | $129,379 | $163,148 | $155,786 | $159,588 | $132,079 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 82,258 | 81,642 | 71,949 | 71,498 | 65,120 |
| Common Shares | 8 | 8 | 7 | 7 | 7 |
| Retained earnings | -1,135,195 | -1,065,961 | -978,980 | -896,805 | -820,191 |
| Other shareholders' equity | -4,194 | 1,800 | 1,501 | 279 | -58 |
| TOTAL | $1,539,637 | $1,579,664 | $946,258 | $971,480 | $786,233 |
| Total Liabilities And Equity | $1,669,016 | $1,742,812 | $1,102,044 | $1,131,068 | $918,312 |